Saturday, March 2, 2024

CATEGORY

Pharma

Bayer’s Lung Cancer Treatment Earns FDA Breakthrough Therapy Designation

Bayer's innovative small molecule tyrosine kinase inhibitor (TKI) BAY 2927088 has received Breakthrough Therapy designation from the FDA for the treatment of unresectable or...

Expanding Horizons in Multiple Myeloma Treatment: CHMP Backs Earlier Application of Carvykti CAR-T Therapy

European drug regulators have given their endorsement for Johnson & Johnson (J&J) and Legend Biotech’s Carvykti to be used earlier in the multiple myeloma...

Simlandi’s Approval Revolutionizes Biosimilar Landscape: A Game-Changer for Humira’s Dominance

Pharmacists in the United States are now granted the authority to substitute a more affordable biosimilar version for AbbVie's high-concentration formulation of Humira without...

Potential Price Cap in State-Level Drug Pricing Strategies by Enbrel Signals Shift

Colorado's prescription drug affordability board's move marks a potential precedent in state-led initiatives to confront high drug pricing, exploring the possibility of capping the...

Ensysce Nears Milestone in Opioid Medication Safety with Promising FDA Discussions on PF614-MPAR

Ensysce Biosciences, a leading innovator in the field of clinical-stage pharmaceutical development, has announced significant progress following a constructive meeting with the Food and...

FDA Priority Review for Breakthrough Biologic Therapy: Dupixent Eyes New Frontier in COPD Treatment

Regeneron Pharmaceuticals and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application...

Sanofi Faces Lawsuit Over Contaminated Rare Disease Treatment After 12 Years

A federal court in Massachusetts has rekindled a lawsuit that has been dormant for nearly twelve years, targeting Sanofi for its alleged role in...

A New Horizon for Ulcerative Colitis Patients in Europe with Pfizer’s Latest Oral Therapy Approval

Pfizer Inc. is thrilled to announce that VELSIPITY® (etrasimod), the first oral therapy of its kind for ulcerative colitis (UC), has received marketing authorization...

Pharmaceutical Giants Respond to FTC Patent System Challenges with Significant Delistings

In response to the Federal Trade Commission's (FTC) November challenge aimed at increasing competition by addressing alleged misuse of the patent system, three pharmaceutical...

FDA Advances Treatment Options for Colorectal Cancer with KRAZATI® and Cetuximab Combo

In a pivotal move for colorectal cancer treatment, the U.S. Food and Drug Administration (FDA) has recently green-lighted a supplemental new drug application for...

Latest news

Sticky Image